Müge AKMANSU, Sevilay İREN, Gül GÜNTÜRKÜN

The Effect of Using Oral Glutamine on the Side Effect of Mucositis in Patients with Head and Neck Cancer Who Are Receiving Chemoradiotherapy: Retrospective Evaluation with Clinical and Immunological Parameters

OBJECTIVEThis study aimed to investigate the effect of glutamine supplementation on the intensity and duration of oral mucositis relatedto therapy and on proinflammatory cytokines in patients with head and neck cancer (HNC) who were treated with chemoradiotherapy (CRT).METHODSIn total, 28 outpatients with HNC (24 male and 4 female) who were admitted to the Gazi University, Department of RadiationOncology, between October 2008 and November 2009 were retrospectively evaluated. The mean age of the patients was 18–76years. All the patients were histopathologically diagnosed with squamous cell carcinoma. Of the 28 patients who were included inthe radiotherapy (RT) program, five were postoperatively included and 23 were included according to organ protection protocols.Eighteen patients prophylactically received oral powdered L-glutamine (Glutamine ResourceR, Nestle) starting from the first dayof RT at a dose of 30 g/day (10 g each at 8-h intervals by mixing with water or fruit juice). For these patients, glutamine supplementation was continued until the completion of RT. Ten patients did not receive any supplementation product. At the initiation ofRT, height and weight were measured for all the patients. The grade of oral mucositis was evaluated using the “Radiation TherapyOncology Group (RTOG)” scoring system. During RT, changes in the weight of patients were routinely evaluated, whereas oralmucositis scoring was performed every week. At the beginning, during, and at the end of the therapy, serum IL-1 beta, IL-6, andTNF-alpha levels were measured, in addition to performing routine blood tests.RESULTSThe incidences of grade 2 mucositis were comparable between the groups who received and did not receive glutamine supplementation (42.1% and 44.4%, respectively). However, the incidence of severe mucositis (RTOG of ≥grade 3) was significantly lowerin the group receiving glutamine supplementation than in the group which did not receive glutamine supplementation (5.3%and 55.6%, respectively; p=0.008). The day of onset of mucositis was the 18th day of the therapy in the group that received glutamine supplementation and 14th in the group that did not receive glutamine supplementation, and this was statistically significant(p=0.007). Similarly, the median dose at which mucositis was started was 36 Gy in the group that received glutamine supplementation and 28 Gy in the group that did not receive glutamine supplementation (p=0.006). The two groups did not show any statistically significant difference in terms of weight change (kg), percentage of weight change, and BMI (kg/m2) when the changes ofweight were examined at the beginning and end of the treatment (p=0.42, p=0.47, and p=0.44, respectively). When the changes inserum TNF-alpha, IL-1 beta, and IL-6 levels were compared at the beginning and end of the treatment, the groups did not showany significant difference (p=0.16, p=0.08, and p=0.77, respectively).CONCLUSIONGlutamine is a well-tolerated supplementation product with proven effects on oral mucositis, which is the side effect occurringduring the therapy of HNCs. The effect of glutamine on inflammation leading to mucositis development in patients with HNCshould be investigated in larger patient populations.

PDF

___

1. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92(8):1341–8.
2. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol 2005;16 Suppl 2:ii258–64.
3. Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, et al. Double-blinded, placebocontrolled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;65(5):1330–7.
4. Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, et al. Oral glutamine to alleviate radiationinduced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 2000;46(3):535–9.
5. Schlemmer M, Suchner U, Schäpers B, Duerr EM, Alteheld B, Zwingers T, et al. Is glutamine deficiency the link between inflammation, malnutrition, and fatigue in cancer patients? Clin Nutr 2015;34(6):1258–65.
6. Kosower NS, Kosower EM. The glutathione status of cells. Int Rev Cytol 1978;54:109–60.
7. Bozzetti F, Biganzoli L, Gavazzi C, Cappuzzo F, Carnaghi C, Buzzoni R, et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition 1997;13(7-8):748–51.
8. Brown SA, Goringe A, Fegan C, Davies SV, Giddings J, Whittaker JA, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998;22(3):281–4.
9. Bunpo P, Murray B, Cundiff J, Brizius E, Aldrich CJ, Anthony TG. Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice. J Nutr 2008;138(2):338–43.
10.Carretero J, Obrador E, Pellicer JA, Pascual A, Estrela JM. Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radic Biol Med 2000;29(9):913–23.
11.Cao Y, Feng Z, Hoos A, Klimberg VS. Glutamine enhances gut glutathione production. JPEN J Parenter Enteral Nutr 1998;22(4):224–7.
12.Welbourne TC. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 1979;57(3):233–7.
13.Rouse K, Nwokedi E, Woodliff JE, Epstein J, Klimberg VS. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 1995;221(4):420–6.
14.Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984;44(10):4224–32.
15.Wolf CR, Lewis AD, Carmichael J, Adams DJ, Allan SG, Ansell DJ. The role of glutathione in determining the response of normal and tumor cells to anticancer drugs. Biochem Soc Trans 1987;15(4):728–30.
16.Hong RW, Rounds JD, Helton WS, Robinson MK, Wilmore DW. Glutamine preserves liver glutathione after lethal hepatic injury. Ann Surg 1992;215(2):114–9.
17.Klimberg VS, Pappas AA, Nwokedi E, Jensen JC, Broadwater JR, Lang NP, et al. Effect of supplemental dietary glutamine on methotrexate concentrations in tumors. Arch Surg 1992;127(11):1317–20.
18.Klimberg VS, Nwokedi E, Hutchins LF, et al. Does glutamine facilitate chemotherapy while reducing its toxicity? Surg Forum 1991;42:16–18.
19.Wolf C, Hayward I, Lawrie S, et al. Cisplatinum-sensitive and resistant ovarian adenocarsinoma cell lines derived from the same patient(abstract). Proc Am Assoc Cancer Res 1985;26:338
20.Ziegler TR, Benfell K, Smith RJ, Young LS, Brown E, Ferrari-Baliviera E, et al. Safety and metabolic effects of L-glutamine administration in humans. JPEN J Parenter Enteral Nutr 1990;14(4 Suppl):137S–146S.
21.Windmueller HG. Glutamine utilization by the small intestine. Adv Enzymol Relat Areas Mol Biol 1982;53:201–37.
22.Panigrahi P, Gewolb IH, Bamford P, Horvath K. Role of glutamine in bacterial transcytosis and epithelial cell injury. JPEN J Parenter Enteral Nutr 1997;21(2):75–80.
23.Pithon-Curi TC, Trezena AG, Tavares-Lima W, Curi R. Evidence that glutamine is involved in neutrophil function. Cell Biochem Funct 2002;20(2):81–6.
24.Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R. Glutamine and glutamate--their central role in cell metabolism and function. Cell Biochem Funct 2003;21(1):1–9.
25.Örnek çalıştay
26.Örnek çalıştay
27.Lievens Y, Haustermans K, Van den Weyngaert D, Van den Bogaert W, Scalliet P, Hutsebaut L, et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998;47(2):149–53.
28.Martin MV, van Saene HK. The role of oral microorganisms in cancer therapy. Curr Opin Dent 1992;2:81–4.
29.Abitbol AA, Sridhar KS, Lewin AA, Schwade JG, Raub W Jr, Wolfson A, et al. Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycinC (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 1997;80(2):266–76.
30.Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990;66(1):62–8.
31.Souba WW, Klimberg VS, Copeland EM 3rd. Glutamine nutrition in the management of radiation enteritis. JPEN J Parenter Enteral Nutr 1990;14(4 Suppl):106S–108S.
32.Shou J, Lieberman MD, Hofmann K, Leon P, Redmond HP, Davies H, et al. Dietary manipulation of methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr 1991;15(3):307–12.
33.Fox AD, Kripke SA, De Paula J, Berman JM, Settle RG, Rombeau JL. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr 1988;12(4):325–31.
34.Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancerchemotherapy. Cancer 1998;83(7):1433–9.
35.Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322–31.
36.Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29(6):501–13.
37.Noé JE. L-glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integr Cancer Ther 2009;8(4):409–15.
38.Cruzat VF, Rogero MM, Tirapegui J. Effects of supplementation with free glutamine and the dipeptide alanyl-glutamine on parameters of muscle damage and inflammation in rats submitted to prolonged exercise. Cell Biochem Funct 2010;28(1):24–30.
39.Fan J, Meng Q, Guo G, Xie Y, Li X, Xiu Y, et al. Effects of glutamine added to enteral nutrition on Peyer’s patch apoptosis in severely burned mice. Burns 2010;36(3):409–17.
40.Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosisfactor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997;41(4):487–93.